ACRS vs DBVT vs PRGO vs IMVT

For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.

8% revenue growth year-over-year, versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). Analysts rate Aclaris Therapeutics, Inc. (ACRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -78. 8% for Aclaris Therapeutics, Inc. (ACRS). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aclaris Therapeutics, Inc.

(ACRS) is the lower-risk stock at 0. 30β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 353% more volatile than ACRS relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.

8% versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). On earnings-per-share growth, the picture is similar: Aclaris Therapeutics, Inc. grew EPS 69. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PRGO leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DBV Technologies S.

A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -829. 6% for Aclaris Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -975. 9% for ACRS. At the gross margin level — before operating expenses — ACRS leads at 73. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

In this comparison, PRGO (9.

8% yield) pays a dividend. ACRS, DBVT, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Aclaris Therapeutics, Inc.

(ACRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 30)). Both have compounded well over 10 years (ACRS: -76. 3%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ACRS is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; PRGO is a small-cap income-oriented stock; IMVT is a small-cap quality compounder stock. PRGO pays a dividend while ACRS, DBVT, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.